Eli Lilly’s mirikizumab triumphs in Phase 3 Crohn’s disease study

Eli Lilly and Company (NYSE: LLY), a pharmaceutical leader, unveiled that mirikizumab, its cutting-edge interleukin-23p19 antagonist, has demonstrated its prowess against placebo in the critical ... Read More